Autores: 
Bujanda L1, Sarasqueta C2, Lanas Á3, Quintero E4, Cubiella J5, Hernandez V6, Morillas JD7, Perez-Fernández T8, Salas D9, Andreu M10, Carballo F11, Bessa X10, Portillo I12, Jover R13, Balaguer F14, Cosme A1, Castells A14; COLONPREV study investigators.

Referencia:
Br J Cancer. 2014 Mar 4;110(5):1334-7. PubMed PMID: 24496455.

BACKGROUND:

We aimed to evaluate whether oral anticoagulants (OACs) alter faecal immunochemical test (FIT) performance in average-risk colorectal cancer (CRC) screening.

METHODS:

Individuals aged 50-69 years were invited to receive one FIT sample (cutoff 75 ng ml(-1)) between November 2008 and June 2011.

RESULTS:

Faecal immunochemical test was positive in 9.3% (21 out of 224) of users of OAC and 6.2% (365 out of 5821) of non-users (P-trend=0.07). The positive predictive value (PPV) for advanced neoplasia (AN) in non-users was 50.4% vs 47.6% in users (odds ratio, 0.70; 95% CI, 0.3-1.8; P=0.5). The PPV for AN in OAC more antiplatelets (aspirin or clopidogrel) was 75% (odds ratio, 2; 95% CI, 0.4-10.8; P=0.4). 

CONCLUSIONS:

Oral anticoagulant did not significantly modify the PPV for AN in this population-based colorectal screening program. The detection rate of advanced adenoma was higher in the combination OAC more antiplatelets.